奥帕韦兰 | 178040-94-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 奥帕韦兰
• 英文名称: Opaviraline
• 英文别名: GW420867X；isopropyl (2S)-7-fluoro-3,4-dihydro-2-ethyl-3-oxo-1(2H)-quinoxalinecarboxylate；(3S)-ethyl-6-fluoro-4-isopropyloxycarbonyl-3,4-dihydroquinoxalin-2(1H)-one；propan-2-yl (2S)-2-ethyl-7-fluoro-3-oxo-2,4-dihydroquinoxaline-1-carboxylate
• CAS: 178040-94-3
• 化学式: C₁₄H₁₇FN₂O₃
• 分子量: 280.299
• InChiKey: KELNNWMENBUHNS-NSHDSACASA-N

物化性质

• 熔点：
  123.5 °C
• 沸点：
  417.7±45.0 °C(Predicted)
• 密度：
  1.204±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (3S)-3-ethyl-6-fluoro-3,4-dihydroquinoxalin-2(1H)-one 、 氯甲酸异丙酯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 以88%的产率得到奥帕韦兰
  参考文献：
  名称：

  Efficient synthesis of useful heterocycles via transition metal-catalyzed cascade processes

  摘要：

  本文报道了我们近期通过过渡金属催化的级联反应合成一些有用杂环化合物，如噁唑啉酮、吲哚和喹喔啉酮的研究结果。同时，讨论了这些方法的应用范围、局限性以及杂环化合物形成反应的机理。

  DOI：

  10.1007/s11164-014-1593-x

文献信息

• A General and Practical Access to Chiral Quinoxalinones with Low Copper-Catalyst Loading
  作者：Shinji Tanimori、Hiroaki Kashiwagi、Takeshi Nishimura、Mitsunori Kirihata

  DOI：10.1002/adsc.201000323

  日期：2010.10.4

  A general, straightforward, and practical access to multi-substituted chiral quinoxalin-2-ones has been achieved based on the copper(I) chloride-dimethylethylenediamine (DMEDA) catalyst system. With the use of 1 mol% copper(I) chloride, structurally diverse quinoxalin-2-ones were generated with high optical purity from readily available starting materials, 2-haloanilines and α-amino acids, in a one-pot

  基于氯化铜（I）-二甲基乙二胺（DMEDA）催化剂体系，已实现了对多取代手性喹喔啉-2-酮的一般，直接和实用的获取。使用1摩尔％的氯化铜（I），可以通过一锅法从容易获得的起始原料2-卤代苯胺和α-氨基酸生成具有高光学纯度的结构多样的喹喔啉-2-酮。
• Quinoxalines, a process for their preparation and their use
  申请人：Hoechst Aktiengesellschaft

  公开号：US05723461A1

  公开（公告）日：1998-03-03

  Disclosed are quinoxalinone compounds of the formula I or Ia ##STR1## and physiologically tolerated salts and prodrugs thereof, in which n=zero, one or two; R.sup.1 =fluorine, chlorine, hydroxyl or C.sub.1 -C.sub.3 -alkoxy; R.sup.2 =C.sub.1 -C.sub.4 -alkyl which is unsubstituted or is substituted by hydroxyl, C.sub.1 -C.sub.4 -alkoxy or C.sub.1 -C.sub.4 -alkylthio; R.sup.3 =C.sub.1 -C.sub.6 -alkyloxycarbonyl or C.sub.2 -C.sub.6 -alkenyloxycarbonyl, and X=oxygen, sulfur or selenium, a process for their preparation and pharmaceutical compositions containing the compounds.

  本发明涉及式I或Ia的喹喔啉酮化合物及其生理耐受的盐和前药，其中n=零、一或二；R1=氟、氯、羟基或C1-C3-烷氧基；R2=C1-C4-烷基，未取代或被羟基、C1-C4-烷氧基或C1-C4-烷基硫取代；R3=C1-C6-烷氧羰基或C2-C6-烯基氧羰基，X=氧、硫或硒。本发明还涉及制备这些化合物的方法以及含有这些化合物的药物组合物。
• Quinoxaline containing medicaments for post exposure prophylaxis of an HIV infection
  申请人：——

  公开号：US20020165233A1

  公开（公告）日：2002-11-07

  Disclosed is the use of an antiviral substance which, when given alone for 14 days, shows a mean initial suppression of viral load by 1.4 log or more and which does not reduce the number of lymphocytes, granulocytes and macrophages as determined by differential blood count after 12 weeks of treatment for the manufacture of a medicament for the immune system-assisted post-exposure prophylaxis of an HIV infection.

  本发明公开了一种抗病毒物质，该物质单独使用 14 天后，病毒载量的平均初始抑制率为 1.4 log 或更高，并且在治疗 12 周后，根据血细胞计数差值确定的淋巴细胞、粒细胞和巨噬细胞的数量不会减少，可用于制造免疫系统辅助的艾滋病毒感染暴露后预防药物。
• Long acting compositions comprising zidovudine and lamivudine
  申请人：Sen Himadri

  公开号：US20050175694A1

  公开（公告）日：2005-08-11

  A pharmaceutical composition in the form of a tablet for controlled release of active ingredient(s) comprises lamivudione, zidovudine or combination of lamivudine and zidovudine or their pharmaceutically acceptable derivatives, and a mixture of hydrophilic polymers selected from the group consisting of at least one hydroxypropyl methylcellulose, at least one sodium alginate and at least one guar gum as controlled release matrix and a pharmaceutically acceptable calcium salt as a matrix stabilizer. The composition may also contain one or more of a water soluble and/or water dispersible diluent, wherein the quantities of the hydrophilic polymers, the calcium salt and water soluble and/or water dispersible diluents are such that the therapeutically effective active ingredient(s) is released at a rate suitable for once daily administration of the pharmaceutical composition. The tablets may be coated with a water soluble polymeric film coat.

  一种用于控制释放活性成分的片剂形式的药物组合物包含拉米夫定、齐多夫定或拉米夫定和齐多夫定的组合物或它们的药学上可接受的衍生物，以及从至少一种羟丙基甲基纤维素、至少一种海藻酸钠和至少一种瓜尔胶组成的组中选出的亲水性聚合物混合物作为控制释放基质和药学上可接受的钙盐作为基质稳定剂。该组合物还可含有一种或多种水溶性和/或水分散性稀释剂，其中亲水性聚合物、钙盐和水溶性和/或水分散性稀释剂的用量应使治疗有效活性成分的释放速度适合每日服用一次该药物组合物。片剂可包覆水溶性聚合物薄膜衣。
• INHIBITORS OF ASPARTYL PROTEASE
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1194404B1

  公开（公告）日：2006-05-03